CANY
CBAY

Caxton Associates (New York)’s Cymabay Therapeutics CBAY Stock Holding History

Caxton Associates (New York)’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,725
Closed -$224K – 692
2023
Q1 		$224K Sell
25,725
-47,924
-65% -$384K 0.04% 398
2022
Q4 		$462K Buy
73,649
+14,225
+24% +$54.1K 0.03% 256
2022
Q3 		$208K Sell
59,424
-45,778
-44% -$164K 0.04% 395
2022
Q2 		$310K Sell
105,202
-12,700
-11% -$30.3K 0.04% 380
2022
Q1 		$367K Buy
+117,902
New +$371K 0.04% 323

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return